Literature DB >> 8943407

Humoral immunity and regulation of intrapulmonary growth of Legionella pneumophila in the immunocompetent host.

J K Brieland1, L A Heath, G B Huffnagle, D G Remick, M S McClain, M C Hurley, R K Kunkel, J C Fantone, C Engleberg.   

Abstract

The potential role of humoral immunity in regulating intrapulmonary growth of Legionella pneumophila in the immunocompetent host was investigated using a murine model of Legionnaires' disease. Intratracheal inoculation of A/J mice with a virulent strain of L. pneumophila (10(6) bacteria per mouse) resulted in the recruitment of B lymphocytes into the lung and the development of anti-L. pneumophila Ab. Opsonization of L. pneumophila in vitro with anti-L. pneumophila-specific mAb resulted in a significant decrease in intrapulmonary growth of the bacteria at 24 to 72 h postinfection. Transmission electron microscopic analysis of lung tissue from L. pneumophila- infected mice demonstrated that while there was no significant difference between phagocytosis of the unopsonized and opsonized L. pneumophila by alveolar macrophages at 24 h postinfection, phagocytosis of opsonized bacteria by alveolar mononuclear phagocytic cells was significantly enhanced at 48 h postinfection. Depletion of A/J mice of complement before intratracheal inoculation of opsonized L. pneumophila (10(6) bacteria per mouse) did not significantly alter intrapulmonary growth of L. pneumophila. These results suggest that anti-L. pneumophila Ab, produced during replicative L. pneumophila lung infections, may regulate intrapulmonary growth of L. pneumophila in the immunocompetent host by decreasing the viability of extracellular L. pneumophila and by enhancing phagocytosis of the bacteria by alveolar mononuclear phagocytic cells by a complement-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943407

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Antibody-mediated elimination of the obligate intracellular bacterial pathogen Ehrlichia chaffeensis during active infection.

Authors:  G M Winslow; E Yager; K Shilo; E Volk; A Reilly; F K Chu
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

Review 2.  Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle.

Authors:  Arturo Casadevall
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 3.  Innate immunity to Legionella and toll-like receptors - review.

Authors:  M Palusinska-Szysz; M Janczarek
Journal:  Folia Microbiol (Praha)       Date:  2010-10-13       Impact factor: 2.099

4.  In vivo regulation of replicative Legionella pneumophila lung infection by endogenous interleukin-12.

Authors:  J K Brieland; D G Remick; M L LeGendre; N C Engleberg; J C Fantone
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

5.  Fc-dependent polyclonal antibodies and antibodies to outer membrane proteins A and B, but not to lipopolysaccharide, protect SCID mice against fatal Rickettsia conorii infection.

Authors:  Hui-Min Feng; Ted Whitworth; Juan P Olano; Vsevolod L Popov; David H Walker
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

6.  IFNγ is Required for Optimal Antibody-Mediated Immunity against Genital Chlamydia Infection.

Authors:  Elizabeth K Naglak; Sandra G Morrison; Richard P Morrison
Journal:  Infect Immun       Date:  2016-09-06       Impact factor: 3.441

7.  Neutrophils Are Central to Antibody-Mediated Protection against Genital Chlamydia.

Authors:  Elizabeth K Naglak; Sandra G Morrison; Richard P Morrison
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

8.  Dynamics of peripheral blood lymphocyte subpopulations in the acute and subacute phase of Legionnaires' disease.

Authors:  Cornelis P C de Jager; Eugenie F A Gemen; Jacqueline Leuvenink; Mirrian Hilbink; Robert J F Laheij; Tom van der Poll; Peter C Wever
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.